Houston, we have a solution
June 3-8

71st ASMS conference

Evosep at ASMS 2023

Learn more about our activities presented at this year’s ASMS below

Scientific presence

Our booth was not the only place to learn more about Evosep and the many research possibilities available with the Evosep One.  We are excited to share several brand-new insights during ASMS 2023.

poster

Rapid and robust PTM peptide mapping for biologics with the Evosep One and the ZenoTOF 7600

poster

Pushing the boundaries for robust and high-throughput single cell analysis with Whisper Flow Technology powered by dia-PASEF

poster

 A complete and automated end-to-end sample preparation strategy for high-throughput and standardized proteomics with high sensitivity

Application note 

Evotip Pure simplifies workflows with excellent reproducibility, storage and recovery

Application note 

End-to-end, fully automated digestion protocol and Evotip Pure workflow on the Opentrons OT-2

Application note 

Fully automated, rapid, robust sample loading on Evotip Pure with the Agilent AssayMAP Bravo

Application note 

Evosep One solves the proteomics dilemma – covering high throughput analysis and proteome depth

Application note 

A standardized separation method with a throughput of 500 samples per day

Application note 

A standardized separation method with a throughput of 300 samples per day

Application note 

A standardized separation method with a throughput of 200 samples per day

Application note 

A standardized separation method with a throughput of 100 samples per day

Application note 

A standardized separation method with a throughput of 60 samples per day

Application note 

A standardized separation method with a throughput of 30 samples per day

Application note 

A specialized method using Whisper Flow technology with a throughput of 80 samples per day

Application note 

A specialized method using Whisper Flow technology with a throughput of 40 samples per day

Application note 

A specialized method using Whisper Flow technology with a throughput of 20 samples per day

Application note 

More proteome coverage in a single experiment with the Extended method

Application note 

A specialized separation method for hydrophobic targets with the High Organic method

Evosep webinar

ASMS 2023 highlights: Automating end-to-end workflows

Available on demand

Get an overview of all the highlights of Evosep at ASMS 2023, including new research, talks and much more from the conference!

Saturday, June 3, 2023 – 5.30 – 9 PM – True Anomaly Brewing CO – 2012 Dallas St, Houston

Evosep User Meeting: Food for thought 

We were thrilled to announce our Evosep One user meeting during this year’s ASMS with informal hours of science presentations, networking and knowledge-sharing.

The Novo Nordisk Foundation logo

High-throughput analysis of deep plasma proteomes by enrichment of extracellular vesicles

Talk by PhD. Ole Østergaard, Proteomics Specialist at Novo Nordisk Foundation Center for Protein Research

Human plasma is an attractive source for protein biomarker discovery as it is in contact with essentially all organ systems in the human body and relatively easy to collect. However, plasma is also a challenging bio-specimen due to the high dynamic range of plasma proteins with quantification of typically only few hundred proteins in standard mass spectrometry (MS)-based proteomics workflow. Extracellular vesicles (EVs) are membrane-enclosed bodies shed constitutively from cells as part of both physiological and pathological processes. Enrichment of EVs from plasma followed by data-independent acquisition (DIA) MS-analysis using fast gradients on the Evosep One LC enables reproducible quantification of 10-fold more proteins from plasma including proteins associated with relevant pathology making this a powerful strategy in clinical proteomics.

Logo Max Planck Institute of Biochemistry

Very large-scale cerebrospinal fluid proteomics for biomarker discovery in multiple sclerosis

Talk by Jakob Bader, PhD student, Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry

Proteomics in body fluids is challenged by the high range of protein abundances and the large cohorts required for biomarker studies. Here, we present a scalable and high-throughput mass spectrometry (MS) proteomics CSF workflow and validate it in a cohort of 6000 CSF samples from patients with various neurological conditions; detecting an average of 1300 proteins per sample. The system is built around the Evosep One chromatography system and the Bruker timsTOF Pro 2, utilizing a 21-minute gradient (60 samples per day) and data-independent acquisition (DIA) scheme. We characterize the robustness of the overall system, including on chromatography level. The large dataset obtained via this scalable workflow synergizes with machine learning to define markers for Multiple Sclerosis.

Accelerating drug development using precision proteomics for patient selection

Talk by Valentina Siino, Senior Scientist at Acrivon Therapeutics Inc.

With cancer being the major cause of death worldwide (Yaffe, 2019; WHO, 2022), and the field of oncology having the highest percentage of failed trials (32%) for drugs in phase II and phase III (Harrison et al. 2016), there is an unmet need for finding specific and reliable biomarkers. 

The Acrivon Predictive Precision Proteomic (AP3) method is specifically designed to overcome the limitations of traditional genetics-based methods and aims to match our precision oncology drug candidates to the patients whose tumors are predicted sensitive to them, independent of underlying genetic alterations. We have used AP3 to generate a predictive protein-based patient selection test, called OncoSignature®, for our lead asset, a CHK1/2 inhibitor that we are advancing in our potentially registrational Phase 2 clinical trial in three solid tumor indications based on predicted sensitivity to ACR-368. The ACR-368 OncoSignature test has been extensively evaluated, including in 2 blinded, prospectively designed biopsy studies on pretreatment tumor biopsies collected from patients with platinum-resistant ovarian cancer previously treated with ACR-368, demonstrating significant enrichment of responders. We have just received Fast Track designation from the Food and Drug Administration for the investigation of ACR-368 as a monotherapy for patients with OncoSignature-positive platinum resistant ovarian and endometrial cancers. 

The AP3 approach leverages unbiased differential global phosphoproteomic drug profiling using mass spectrometry and quantitative multispectral in situ imaging of tumor models, patient samples and clinical trial biopsies, to identify and evaluate biomarkers. The AP3 platform is also used to generate robust data outputs that result from analyzing benchmark clinical-stage compounds for the rational design of our preclinical drug candidates in parallel with developing patient selection capabilities, indication finding, rational drug combinations and drug resistance mechanisms. 

evosep-logo

A complete and automated end-to-end sample preparation strategy for high-throughput and standardized proteomics

Talk by Dorte Bekker-Jensen, Scientist at Evosep

Proteomics is going through a significant paradigm shift and is rapidly evolving towards higher throughput and robust easier-to-use technologies. The use of short LC gradients combined with data-independent acquisition (DIA) has been a key aspect in this development. The Evosep One is designed for high-throughput and high-volume applications, where standardized methods with increasing robustness enable routine analysis of hundreds of proteomes per instrument per day. This has shifted the bottleneck for realizing high-throughput proteomics towards sample preparation creating a need for rapid, robust, and reproducible end-to-end automated workflows. Here, we combine our fully automated loading strategy for Evotips with fully automated sample handling functionalities in a modular setup and using it with protein aggregation capture (PAC) assisted digestion in an end-to-end standardized workflow.

 

evosep-logo

Nicolai Bache, Head of Applications at Evosep (host)

monday, june 5, 2023 – 7:00 – 8:15 AM – room 310BC – George R Brown Convention Center

Evosep Breakfast Seminar: standardizing high-throughput proteomics

Logo Max Planck Institute of Biochemistry

Clinical proteomics workflows enabled by the Evosep system

Talk by Professor Matthias Mann, Max-Planck Institute of Biochemistry, Proteomics and Signal Transduction

Although the basic set up of mass spectrometry – based proteomics has essentially stayed the same over two decades, the capabilities of this technology have increased exponentially. Currently this manifests mainly in the areas of throughput, robustness and sensitivity, each of which the Evosep system has profoundly impacted. In our group, we have now nearly completely shifted to short gradients (typically 60 samples per day) and to commercial columns (typically Pepsep or IonOptiks but also uPAC). The shift from home built set ups to a more standardized format has tremendously accelerated our research without decreasing performance. It also coincides with increasingly faster MS instruments such as the Bruker, Thermo or SCIEX platforms. In turn, this has enabled us to tackle increasingly large-scale clinical studies, including thousands of plasma or CSF samples, some result of which will be described here. Furthermore, we routinely use the low flow Whisper gradients for single cell analysis or any other ultra-high sensitivity analyses. Our main focus now is the ‘Deep Visual Proteomics’ technology, where we combine AI based segmentation and classification of cells in tumor tissues with automated laser micro dissection and mass spectrometry. 

Integration of chip-based sample preparation and high-throughput chromatography enables single-cell chemical proteomics

Talk by Claudia Ctortecka, Postdoc at Broad Institute of MIT and Harvard

Our most recent miniaturized single-cell proteomics (SCP) workflow integrates a dedicated proteoCHIP directly with the Evosep One. The nanoliter sample preparation with 40SPD and diaPASEF acquisition quantifies more than 3,000 proteins per single cell. These identifications are highly reproducible with cumulative missing values of ≤10% spanning over 4 orders of magnitude. This proteome depth is sufficient to represent dose dependent small-molecule effects and identifies targeted compound perturbations. Moreover, we demonstrate that even 80SPD can be effectively used for rapid screening while recovering 75% of protein identifications and biologically relevant targets.

MEET THE TEAM

This year we had representatives from our Applications-, Management-, Sales- and Product team.
Learn a little bit about the team at ASMS 2023 here. 

Nicolai Bache

Nicolai Bache

Head of Applications

Dorte Bekker-Jensen

Dorte Bekker-Jensen

Senior Scientist

Michael BarRett Andersen

Michael BarRett Andersen

Head of Product Management

Erik Verschuuren

Erik Verschuuren

Head of Global Sales

Ole Vorm

Ole Vorm

Founder

Christian Ravnsborg

Christian Ravnsborg

CEO

Laurent Rieux

Laurent Rieux

Product Specialist

Thomas Carrell

Thomas Carrell

Sales Specialist

John Lindsay

John Lindsay

Sales Representative

Craig Bury

Craig Bury

Sales Representative

Magnus Huusfeldt

Magnus Huusfeldt

Scientist

Britta Diedrich

Britta Diedrich

Sales Specialist

Ole Bjeld Hørning

Ole Bjeld Hørning

Head of Technology

Andreas Hermannsen

Andreas Hermannsen

Digital Marketing Specialist

News

(May 2023) Evosep Launches End-to-End Proteomics Workflow, Setting a new Standard for Automated Sample Preparation

At ASMS 2023 Evosep, a leading provider of innovative solutions for proteomics research, proudly announces the release of End-to-End Proteomics Workflow. 

(May 2023) EVOSEP AND CELLENION ENTER CO-MARKETING AGREEMENT TO BOOST SINGLE CELL PROTEOMICS

Singapore – AOHUPO (May 9th, 2023). Evosep is pleased to announce a new co-marketing partnership with Cellenion. This partnership will enable researchers to access a complete solution for single-cell proteomics, combining Evosep’s cutting-edge liquid chromatography technology with Cellenion’s advanced single-cell isolation and sample preparation platform.

(March 2023) Evosep and Resyn Biosciences partner to integrate their technologies into new clinical proteomics solutions

ReSyn Biosciences and Evosep have recently demonstrated several joint solutions thatintegrate automated sample purification with liquid chromatography coupled mass spectrometry.

(March 2023) Evosep ESTABLISHES CENTER OF EXCELLENCE FOR HIGH-THROUGHPUT AND STANDARDIZED PROTEOMICS

Evosep Biolabs will partner with key players in the proteomics area, execute end-to-end workflows on customer projects, remove barriers to entry by acting as an external, expert lab partner, as well as providing extra, ad-hoc capacity to established organizations.

(January 2023) EVOSEP RECEIVES STRATEGIC INVESTMENT FROM NOVO HOLDINGS A/S TO ACCELERATE ITS EFFORT ON CLINICAL PROTEOMICS

Odense, Denmark – Evosep Aps (January 9, 2023) – Evosep today announced that Novo Holdings A/S has become a minority shareholder in Evosep Aps with a US$ 40m investment to further Evosep’s technology and application portfolio for clinical proteomics.

(December 2022) Evosep adds automation to its standardized platform

Cancun, Mexico – HUPO 2022. Today, at the 21st Human Proteome Organization World Congress, Evosep launches new separation methods and a protocol for automated loading of Evotips enabling end-to-end high throughput proteomics workflows.

LET’S GET IN TOUCH

We are always open to answering questions and form new collaborations, so don’t hesitate to reach out. Fill out our contact form and we’ll do our very best to assist you.